4-[[4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基]甲基]哌嗪-1-羧酸叔丁酯 | 936694-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-[[4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基]甲基]哌嗪-1-羧酸叔丁酯
• 中文别名: 4-(4-Boc-1-哌嗪甲基)苯硼酸频哪醇酯
• 英文名称: tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperazine-1-carboxylate
• CAS: 936694-19-8
• 化学式: C₂₂H₃₅BN₂O₄
• mdl: MFCD16294502
• 分子量: 402.342
• InChiKey: AAEYFMAHSYKHGD-UHFFFAOYSA-N

物化性质

• 熔点：
  125-130 °C
• 沸点：
  486.5±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.35
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.681
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(4-Boc-Piperazinomethyl)phenylboronic acid, pinacol ester
Product Name:
Synonyms: tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(4-Boc-Piperazinomethyl)phenylboronic acid, pinacol ester
Ingredient name:
CAS number: 936694-19-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C22H35BN2O4
Molecular weight: 402.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[[4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基]甲基]哌嗪-1-羧酸叔丁酯 在 盐酸 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 potassium carbonate 、 caesium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 61.5h， 生成 (2R,3S,4R,5S)-N-(4-((3-(4-(4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)benzyl)piperazin-1-yl)propyl)carbamoyl)-2-methoxyphenyl)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamide
  参考文献：
  名称：

  [EN] SMARCA DEGRADERS AND USES THEREOF
  [FR] AGENTS DE DÉGRADATION DE SMARCA ET LEURS UTILISATIONS

  摘要：

  本发明提供化合物、其药学上可接受的组合物，以及利用这些化合物调控一个或多个SWI/SNF相关基质相关肌动蛋白依赖的染色质亚家族A（SMARCA）和/或聚溴-1（PB-1）蛋白通过化合物的泛素化和/或降解的方法。这些化合物是双功能分子，将结合到cereblon的部分与结合到SMARCA和/或PB1蛋白的配体连接在一起。

  公开号：

  WO2020251971A1
• 作为产物：
  描述：

  N-Boc-哌嗪 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 4-[[4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基]甲基]哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof

  摘要：

  本公开提供了式(I)的杂环双环化合物，它们的互变异构体、多晶形态、立体异构体、前药、溶剂合物、水合物、N-氧化物、共晶体、药学上可接受的盐、含有它们的药物组合物以及治疗由Bruton's酪氨酸激酶（Btk）活性介导的疾病和病症的方法。该公开还涉及制备式(I)化合物的过程。 这些化合物在治疗、预防、预防、管理或辅助治疗与Bruton's酪氨酸激酶（Btk）抑制相关的所有医学状况方面具有用处，如炎症和/或自身免疫性疾病、细胞增殖、类风湿关节炎、银屑病、银屑病性关节炎、移植排斥、移植物抗宿主病、多发性硬化、炎症性肠病、过敏性疾病、哮喘、1型糖尿病、重症肌无力、造血功能障碍、B细胞恶性肿瘤、系统性红斑狼疮或其他疾病。

  公开号：

  US20150064196A1
• 作为试剂：
  描述：

  5-bromo-N-butyl-7-(trans-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 、 N-Boc-4-氨基苯硼酸频哪醇酯 在 bis-triphenylphosphine-palladium(II) chloride 、 4-[[4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基]甲基]哌嗪-1-羧酸叔丁酯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以58.3%的产率得到
  参考文献：
  名称：

  使用MERi-SiR的Mer酪氨酸激酶（MERTK）的近红外成像显示转移性疾病中肿瘤相关的巨噬细胞摄取

  摘要：

  受体酪氨酸激酶Mer（MERTK）是癌症中有希望的药物靶标，它可以影响肿瘤细胞和免疫细胞的转移促进信号。但是，目前不存在小分子探针可选择性地对Mer成像。在这项工作中，我们设计并合成了Mer（MERi-SiR）选择性近红外荧光分子探针。小鼠转移灶的共聚焦显微镜显示在表达Mer的肿瘤相关巨噬细胞中主要存在探针积累。

  DOI：

  10.1039/c7cc07581b

文献信息

• 降解EZH2蛋白的小分子化合物
  申请人：清华大学

  公开号：CN111303133A

  公开（公告）日：2020-06-19

  本发明提出了一种化合物，其为式I所示化合物或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或前药：其中，X表示EZH2蛋白的配体，Z表示E3连接酶的配体，Y表示连接X和Z的链。本发明所提出的化合物是一种可以降解EZH2的PROTAC分子，与已有的EZH2抑制剂相比，本发明涉及的小分子化合物具有快速抑制肿瘤增殖的能力，有潜力成为治疗恶性肿瘤的有效治疗方式。X‑Y‑Z 式I。
• [EN] MERTK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE MERTK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020010210A1

  公开（公告）日：2020-01-09

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• [EN] SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS HÉTÉRO-BICYCLIQUES SUBSTITUÉS, COMPOSITIONS ET LEURS APPLICATIONS MÉDICINALES
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2013157022A1

  公开（公告）日：2013-10-24

  The present disclosure provides hetero-biclyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.

  本公开提供了式(I)的杂环双环化合物，它们的互变异构体、多晶形态、立体异构体、前药、溶剂合物、水合物、N-氧化物、共晶体、药学上可接受的盐、含有它们的药物组合物以及治疗由布鲁顿酪氨酸激酶（Btk）活性介导的疾病和病症的方法。该公开还涉及制备式(I)化合物的过程。这些化合物在治疗、预防、预防、管理或辅助治疗与抑制布鲁顿酪氨酸激酶（Btk）有关的所有医学状况方面具有用处，如炎症和/或自身免疫性疾病、细胞增殖、类风湿关节炎、牛皮癣、银屑病性关节炎、移植排斥、移植物抗宿主病、多发性硬化、炎症性肠病、过敏性疾病、哮喘、1型糖尿病、重症肌无力、造血功能障碍、B细胞恶性肿瘤、系统性红斑狼疮或其他疾病。
• DIPHENYL DERIVATIVES AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：US20190077773A1

  公开（公告）日：2019-03-14

  The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开提供了一种公式(I)的化合物： 或其药用可接受的盐，以及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退化和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• TNF -Alpha Modulating Benzimidazoles
  申请人：UCB Biopharma SPRL

  公开号：US20150152065A1

  公开（公告）日：2015-06-04

  A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列苯并咪唑衍生物，作为人类肿瘤坏死因子α活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。